MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
News Dec 12, 2008
MorphoSys AG has announced that its licensing partner, Centocor R&D Inc., has enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody. A Phase 1 clinical trial using the same antibody in oncology patients was initiated in 2007 and is ongoing.
The new trial is in an immunology indication. This achievement marks the first antibody, developed with MorphoSys's core technology, to enter human clinical trials in a second indication with partners. The initiation of the Phase 2 trial and the IND in a new indication trigger clinical milestone payments to MorphoSys.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018